Holly L. Cranmer
Sheffield, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Caring for and Caring about in Economic Evaluation: Modelling the Family and Caregiving Effects.
Journal: PharmacoEconomics
Published: June 06, 2025
Including carer health-related quality of life in NICE health technology assessments in the United Kingdom.
Journal: Health economics, policy, and law
Published: October 08, 2024
An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology.
Journal: Applied health economics and health policy
Published: January 22, 2023
Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.
Journal: Haematologica
Published: January 20, 2023
Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Journal: Hematology (Amsterdam, Netherlands)
Published: January 06, 2023
Cost-effectiveness of home-based cardiac rehabilitation: a systematic review.
Journal: Heart (British Cardiac Society)
Published: November 25, 2022
The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
Journal: Journal of managed care & specialty pharmacy
Published: August 24, 2022
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.
Journal: Current medical research and opinion
Published: July 11, 2022
Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin.
Journal: PharmacoEconomics - open
Published: June 14, 2022
Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer.
Journal: Future oncology (London, England)
Published: May 24, 2022
Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.
Journal: Journal of comparative effectiveness research
Published: December 09, 2021
A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology.
Journal: Journal of medical economics
Published: July 17, 2020
Last Updated: 09/26/2026